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n-3 PUFA omega-3 polyunsaturated fatty acid 
NCEP National Cholesterol Education Program 
OR odds ratio 
PAI-1 plasminogen activator inhibitor type-1 
PPAR peroxysome proliferator activated receptor 
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TNF- tumor necrosis factor- 
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4. Introduction 
4.1. Classification and epidemiology 
4.1.1. The metabolic syndrome 
The metabolic syndrome is a cluster of risk factors for cardiovascular disease (CVD), including 
abdominal obesity, elevated glucose, hypertension, elevated triglycerides and low levels of high-
density lipoprotein (HDL) cholesterol. The syndrome has received increased attention after 
practical and updated definitions by the Adult Treatment Panel III (ATP III) and the International 
Diabetes Federation (IDF) (Table 1) (1-3). Although other classifications exist, and the criteria 
vary to some degree, all definitions identify a population with increased risk for developing type 
2 diabetes mellitus and CVD (4-6).  
 
Table 1. Common definitions of the metabolic syndrome. Adapted from Grundy SM (7). 
WHO (1998) NCEP/ATP-III (2001/2005) IDF (2005) 
Insulin resistance or diabetes/impaired 
glucose tolerance (IGT)/impaired fasting 
glucose (IFG)* plus 2 of: 
 Blood pressure  140/90 or 
treatment. 
 Triglycerides  1.7 mmol/L or 
HDL < 0.9 (women)/1.0 (men) 
mmol/l. 
 BMI  30 kg/m2 or waist/hip 
ratio > 0.9 (men)/0.85 
(women) 
 Microalbuminuria 
At least 3 of the following: 
 Waist circumference>102 
(men)/88 cm (women) 
 Triglycerides > 1.7 mmol/L 
 HDL < 1.0 (men)/ 1.3 
(women) mmol/L 
 Blood pressure > 130/85 
mmHg or treatment. 
 Glucose > 5.6** mmol/L or 
treatment. 
Waist circumference  94 (men)/ 80 
(women) cm*** plus 2 of: 
 Blood pressure > 130/85 
mmHg or treatment. 
 Triglycerides > 1.7 mmol/L 
or treatment. 
 HDL < 1.0 (men)/ 1,3 
(women) mmol/L. 
 Glucose > 5.6 mmol/L or 
treatment. 
*See table 2 for definitions of IGT and IFG. ** Cut-off changed from 6.1 mmol/l (2001) according to updated definition of 
IFG. ***The IDF definition has population specific cut-offs for waist circumference. 
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Whereas the original definition by Reaven (1988) (8), as well as the definition by the World 
Health Organisation (1998) emphasised insulin resistance as mandatory for the diagnosis, no 
measure of insulin resistance is present in the updated definitions by IDF and ATP-III (2005) 
(9). Instead, the role of central obesity measured by waist circumference has been given more 
attention, and is mandatory by the IDF criteria. A few comparative studies have aimed to 
compare the various definitions, and it seems that the IDF-definition identifies slightly more 
individuals with the syndrome (10-12).  
 
Physical inactivity and increased caloric intake have led to an emerging epidemic of obesity. 
In the United States abdominal obesity has tripled during the past 40 years (13), more than 
25% of the US population can be classified as having the metabolic syndrome (14), and the 
prevalence is increasing (15). Depending on which classification that has been used, similar 
prevalence of the syndrome can be found in India and several countries in Europe, whereas 
the prevalence is even higher in some Latin-American countries (21 to 43%) and lower in 
South-East Asia (7). The prevalence is also increasing with age, affecting >40% of US adults 
above the age of 60 years (16). Similar age-related prevalence has been shown in a 
Norwegian cohort, increasing from 13% in the 20-29 year age group to 41% in the 70-79 
years age group in men, and from 6% to 51% for women in the corresponding age groups 
(ATP III criteria) (Figure 1) (17).  
 
As all the individual components of the syndrome have been shown to increase the risk of 
CVD, including elevated fasting glucose (18), abdominal obesity (19), hypertension (20), 
elevated triglycerides (21) and low levels of HDL cholesterol (22), it has been discussed if the 
metabolic syndrome is a useful clustering of risk factors (23), and if the  
 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Age-specific prevalence of the metabolic syndrome in Norway. Adapted from 
Hildrum B (17). 
 
syndrome really exists (24). Furthermore, different combinations of these components might 
identify very different phenotypes, although the diagnostic criteria of the syndrome are 
fulfilled (9).  
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Table 2. American Diabetes Association criteria for diagnosis of diabetes and impaired 
glucose regulation. Adapted from Genuth S (25) .  
Category Fasting plasma glucose 2-hour post-load plasma 
glucose 
Normal < 5.6 mmol/L < 7.8 mmol/L 
Impaired fasting glucose (IFG) 5.6-6.9 mmol/L - 
Impaired glucose tolerance (IGT) - 7.8-11.0 mol/L 
Diabetes mellitus > 7.0 mmol/L  > 11.1 mmol/L  
 
As an example, elevated fasting glucose is a more useful marker for increased risk of diabetes 
mellitus than any of the other components (9, 26). The metabolic syndrome is a strong 
predictor of type 2 diabetes, with an increased incidence rate of 5 to 7-fold (26, 27). Indeed, 
the increased cardiovascular risk might develop as a continuum in parallel with increasing 
fasting glucose, from the normal range via impaired fasting glucose to overt diabetes mellitus 
(Table 2) (28).  
 
The risk of developing CVD is approximately doubled in the metabolic syndrome (7). 
Importantly, subjects with the syndrome may be classified as having low risk of CVD by both 
the Framingham score and the European Systematic Coronary Risk Evaluation (SCORE) but 
still be at increased risk of subclinical atherosclerosis and cardiovascular events (29-31). In a 
recent meta-analysis including 43 cohorts, the relative risk for cardiovascular events and 
death was 1.78, with the highest risk in women (relative risk 2.63) (32). After adjustment for 
traditional risk factors like hypercholesterolemia and smoking, the syndrome was still 
associated with increased risk (relative risk 1.54).  
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      4.1.2. Atherosclerosis  
Atherosclerosis is a systemic disease affecting large and medium-sized arteries, with 
dominating clinical symptoms from the heart, brain and extremities (33), including the aorta. 
Atherosclerotic lesions are asymmetrical focal thickenings of the innermost layer of the 
intima, consisting of cells, connective-tissue elements, lipids and debris (34). The lesions tend 
to develop in areas in the vasculature with disturbed non-laminar flow (35).  
 
Most cardiovascular events occur with the formation of a thrombus on the plaque surface 
(36). Thrombosis is caused by either endothelial erosion or rupture of the plaque. Plaque 
rupture occurs most often in thin and partly destroyed parts of the fibrous cap, exposing pro-
thrombotic material such as tissue factor and platelet-adhesive matrix molecules to the 
circulation (37). 
 
Atherothrombosis underlies by far most cases of coronary heart disease and peripheral arterial 
occlusive disease, as well as many cases of stroke (38). Thus, atherosclerosis and its 
thrombotic complications are the main causes of death and disabling diseases in Europe, the 
United States and much of Asia (39, 40). At present, CVD cause almost 40 percent of all 
deaths in North America and are the most common cause of death in European men under 65 
years, and the second most common cause in women (41). Furthermore, due to a rapidly 
increasing prevalence of obesity and diabetes, CVD is expected within the coming years to be 
the leading cause of death globally (39, 40).  
 
The progression of atherosclerosis is partly dependent on genetic susceptibility and the 
presence of risk factors such as smoking, hypertension, diabetes mellitus and dyslipidemia 
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(38). Elevated plasma levels of low density lipoprotein (LDL) cholesterol have been one of 
the principal cardiovascular risk factors, and the atherosclerotic lesion has previously been 
thought to largely consist of lipid accumulation within the arterial wall (33). Notably, half of 
coronary events occur in persons with normal lipid levels (39), and our understanding of the 
atherosclerotic process has changed substantially during the last two decades. 
 
4.2. Inflammation in atherosclerosis and the metabolic syndrome 
4.2.1. Atherosclerosis - an inflammatory process 
It is now evident that inflammation plays an essential role in atherosclerosis, and leukocyte 
infiltration into the vascular wall is involved in virtually all stages of the process, from the 
fatty streak to the complex rupture-prone plaque (33). The atherosclerotic process starts in 
early life, with T-lymphocytes and lipid-containing macrophages (foam cells) accumulating 
beneath the endothelium, gradually being organised in layers to form fatty streaks, which are 
asymptomatic lesions that may progress to atheromata or disappear (41-43). In the stable 
atherosclerotic lesion, inflammatory cells are present in the shoulder region of the 
atherosclerotic plaque, in which the atheroma grows, whereas in the unstable plaque, 
activated immune cells preferentially occur in thin, rupture-prone areas (41).  
 
The endothelium does normally not support binding and transmigration of leukocytes, but 
might be dysfunctional and leaky by exposure to several injuries such as hypertension, 
hyperglycemia, free radicals from smoking and modified lipids (33, 44). Modified lipids, 
such as oxidised LDL have been shown to induce expression of cellular adhesion molecules,  
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Figure 2. Oxidation of LDL cholesterol and activation of endothelium and macrophages. 
Spikes on endothelium surface represent adhesion molecules. Adapted from Hansson G (41).   
 
such as E-selectin, P-selectin, intercellular adhesion molecule-1 and vascular cellular 
adhesion molecule-1, on the surface of endothelial cells (Figure 2) (45-48). Leukocytes and 
platelets from the blood stream attach to these adhesion molecules, and once attached, 
chemokines such as interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) 
stimulate the transmigration of monocytes and T-lymphocytes to the subendothelial space 
(49-51) (Figure 3). Inflammatory mediators such as MCP-1 and macrophage colony-
stimulating factor contribute to the differentiation of blood monocytes to macrophages, and to 
the expression of scavenger receptors leading to uptake of modified lipids and the formation 
of foam cells (52-54). 
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Figure 3. Transmigration of leukocytes. Spikes on endothelium surface represent adhesion 
molecules. Chemokines such as IL-8 and MCP-1 stimulate the adhesion and transmigration 
of leukocytes to the subendothelial space. Adapted from Hansson G (41).  
 
In the atherosclerotic process, endothelial cells, smooth muscle cells, T-cells and 
macrophages have the potential to secrete proinflammatory cytokines such as tumor necrosis 
factor- (TNF-) and IL-6, as well as IL-10 (33, 55, 56). T-lymphocytes are present in the 
atherosclerotic lesion, and when activated, a type 1 helper (Th1) response dominates, with 
production of a characteristic subset of inflammatory mediators, such as interferon-, IL-12, 
IL-18, TNF- and CD40 ligand, which act in synergy to stimulate a cascade of cytokines 
from macrophages and vascular cells (41, 57).  
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Figure 4. The atherosclerotic plaque and adipose tissue as sources of systemic inflammation. 
Adapted from Hansson G (41).  
 
Activation of the Th2 pathway leads to production of IL-4, IL-5 and IL-13, a cytokine subset 
which might have both pro- and anti-atherogenic effects (57-59). In addition, regulatory T-
cells might produce anti-inflammatory agents such as IL-10 and transforming growth factor  
which might dampen the inflammatory process (57, 60-63).  
 
The inflammatory process in the atherosclerotic plaque may increase blood levels of 
inflammatory cytokines downstream in the cytokine cascade (Figure 4). In particular, C-
reactive protein, which is produced in the liver in response to inflammatory stimuli like IL-6, 
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has been consistently shown to be elevated in patients with coronary events (64, 65), and 
there is evidence for a direct role in the atherosclerotic process (66, 67).  
 
IL-18 is a potent pro-inflammatory cytokine which is involved in the Th1 response, and a role 
in plaque destabilisation has been suggested (68, 69). IL-18 is thought to exert its main pro-
atherogenic effects by inducing interferon- production, which potentiates the inflammatory 
process and may lead to thinning or inhibition of the fibrous cap formation, resulting in 
vulnerable, rupture-prone plaques (57, 70). In addition, IL-18 increases the expression of 
matrix metalloproteinases in vascular cells and macrophages, which might also contribute to 
plaque destabilisation (57, 71). However, data regarding IL-18 as a potential predictor of 
acute cardiovascular events have so far been conflicting (72, 73).  
 
4.2.2. The metabolic syndrome - a pro-inflammatory state 
There is increasing evidence that the metabolic syndrome is associated with a chronic, low-
grade inflammation (3). Several pro-inflammatory cytokines have been shown to be elevated 
in parallel with an increasing number of components of the syndrome, whereas the anti-
inflammatory and adipocyte-specific substance adiponectin is consistently lower (74-77). 
Furthermore, pro-inflammatory cytokines have been reported to induce insulin resistance in 
both adipose tissue and muscle (78-80). Moreover, increased levels of CRP, IL-6 and low 
levels of adiponectin have been shown to predict the development of type 2 diabetes mellitus 
(81, 82). Recently, also IL-18 was reported to predict type 2 diabetes (83).  
 
Some investigators have discussed that both type 2 diabetes, metabolic syndrome and 
atherosclerosis are multifactorial conditions which appear to have a common inflammatory 
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basis (84). And as both inflammation and the metabolic syndrome are known risk factors for 
CVD, it is currently discussed if a measure of inflammation should be included in the 
definition of the syndrome (3, 85).  
 
So far, CRP has been the most likely candidate (85, 86). Cross-sectional and prospective 
studies have shown added prognostic information for cardiovascular risk stratification with 
CRP in populations with the metabolic syndrome (87-89). However, a recent prospective 
study showed that although both CRP and the metabolic syndrome were independent 
predictors of CVD, the combination of the two did not increase the predictive value (90). The 
role of other pro-inflammatory markers in predicting CVD in populations with the metabolic 
syndrome remains to be investigated.  
 
In addition to a pro-inflammatory state, the metabolic syndrome is frequently accompanied by 
a hypercoagulable state with increased plasma coagulation and reduced fibrinolysis (91, 92). 
In particular, the main inhibitor of the fibrinolytic system, plasminogen activator inhibitor 
type-1 (PAI-1), has been consistently shown to be elevated in the metabolic syndrome (93). 
Thus, the metabolic syndrome can in part be considered both a pro-inflammatory and pro-
thrombotic state (3). 
 
4.2.3. Adipose tissue - an important source of inflammation  
The classical perception of adipose tissue as a passive storage place of fatty acids has 
gradually been replaced by the notion of adipose tissue, and visceral fat in particular as an 
active endocrine organ. Visceral fat is now considered a central feature and potential cause of 
the metabolic syndrome (9), in part mediated by release of a large number of metabolically 
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active substances known as adipokines (Figure 4). Adipokines are involved in several 
biological processes, including inflammation, thrombosis, insulin sensitivity and energy 
balance (94). Not only adipocytes, but also stromal cells such as macrophages, fibroblasts and 
endothelial cells are involved in the production of various adipokines (95). Several pro-
inflammatory markers have been shown to be produced in adipose tissue, including MCP-1, 
TNF-, IL-1, IL-6, IL-8 and IL-18 (Figure 4) (96, 97). In the presence of obesity, adipose 
tissue produces cytokines in excess, whereas the production of adiponectin is diminished, 
thus shifting the balance to a pro-inflammatory state (98).  
 
Whether systemic inflammation depends mostly on the quantity or the quality of adipose 
tissue is not known, but probably the quantity of visceral adipose tissue is important (95). In 
contrast to subcutaneous fat, visceral fat drains directly to the portal circulation, and a study 
in extremely obese patients indicated that visceral fat was the main contributor of plasma IL-6 
levels (99). Thus, in obese people, it is likely that viscerally produced IL-6 drained via the 
portal circulation could be an important inductor of CRP-production in the liver (95, 96). 
 
Moreover, IL-6 has been shown to induce PAI-1 production in visceral and subcutaneous 
adipose tissue (100). PAI-1 is produced in substantial amounts in human adipose tissue (101, 
102), and in a study of obese patients abdominal visceral fat expressed 5-fold more PAI-1 
than subcutaneous fat (103). Hence, adipose tissue is likely to be a major contributor to the 
pro-inflammatory, pro-thrombotic state characteristic of the metabolic syndrome. 
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4.3. Arterial stiffness and the metabolic syndrome 
Changes in arterial elasticity are present throughout the atherosclerotic process, and are 
closely associated with endothelial dysfunction (104). Non-invasive measurements of arterial 
distensibility in various vascular segments may be performed by several methods, including 
pulse wave velocity or the inversely related pulse wave propagation time (PWP) (105). Such 
measurements of arterial stiffness have been shown to predict cardiovascular events in several 
studies. Most evidence comes from measurement of aortic pulse wave velocity in various 
populations (106-112), whereas one study reported predictive information of small artery 
elasticity in an asymptomatic population (113). Although measures of arterial stiffness may 
give prognostic information, it remains to demonstrate whether reducing arterial stiffness 
with treatment might reduce the risk of cardiovascular events (114). Aging affects all 
segments of the vasculature, and should be taken into account when arterial stiffness is 
evaluated in relation to the atherosclerotic process (114).  
 
Arterial stiffness is a central feature in both type 1 and type 2 diabetes mellitus (115). In type 
2 diabetes, the presence of micro- and macrovascular complications is associated with 
increase in arterial stiffness (116, 117). Furthermore, the age-related increase in arterial 
stiffness is steeper in individuals with type 2 diabetes than controls (118).  
 
An increasing amount of evidence has also demonstrated increased arterial stiffness in 
subjects with the metabolic syndrome, associated with increasing number of components of 
the syndrome (119-123). Also in subjects with the metabolic syndrome, there seems to be a 
steeper age-related increase in arterial stiffness (119). Of note, individuals with improved 
metabolic status over time have experienced lower rates of arterial stiffness (122). Taken 
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together, arterial stiffness seems to be closely associated with the metabolic syndrome, and 
has been suggested to contribute to the increased cardiovascular risk in this population (115).  
Although low-grade inflammation is known to impair endothelial function (124), little is 
known about a potential mediating role of inflammation on the metabolic syndrome and 
diabetes-related arterial stiffness (115).  
 
4.4. Non-pharmacological interventions 
4.4.1. Preventive effects of life style modifications 
Lifestyle modifications have been shown to reduce the risk of developing type 2 diabetes. In 
the Finnish Diabetes Prevention Study, 552 middle-aged, overweight patients with impaired 
glucose tolerance, 76% with the metabolic syndrome, were randomised to an intervention 
group (aimed at reducing weight, reducing fat intake, increasing fibre intake and increasing 
physical activity) or a control group. During 3.2 years of follow-up, the intervention group 
had a 58% reduction in the risk of developing diabetes (125, 126). Similar results were 
reported from the Diabetes Prevention Program in the United States, where lifestyle 
modifications (aiming at weight reduction and increased physical activity) reduced diabetes 
risk with 58% compared with controls (127). 
 
Physical inactivity and reduced physical fitness have been identified as independent risk 
factors of CVD, and are also clustered with other risk factors (128-130). Also changes in 
physical fitness over time are associated with all-cause and cardiovascular mortality (131). In 
large prospective observational studies, increased physical activity has been associated with 
reduced all-cause and cardiovascular mortality (132, 133). Thus, the importance of physical 
activity is highlighted in international guidelines on primary and secondary prevention of 
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CVD (134, 135). Still, the guidelines are not clear concerning the necessary dosage of 
training, although even small doses seem to be preventive (136).  
 
4.4.2. Prevention of cardiovascular events by omega-3 fatty acids and Mediterranean-
like diet 
Polyunsaturated fatty acids (PUFAs) are defined as fatty acids containing two or more double 
bonds, and are classified as n-3 or n-6 according to the location of the first double bond 
relative to the methyl end of the molecule (137). Increased intake of n-3 PUFAs from plants 
or fish is a central feature of the Mediterranean dietary pattern, which is also characterised by 
reduced intake of saturated fat and high intake of fresh fruit, vegetables and cereals (138). 
Mediterranean-like diet and n-3 PUFA supplementation have been reported to reduce the risk 
of cardiovascular morbidity and mortality (139). In the DART trial comprising 2033 patients 
with previous myocardial infarction, a 29% decrease in all-cause mortality was observed in 
men who were randomised to eat fatty fish twice a week compared to a control group (140). 
In the large GISSI secondary prevention trial, a 30% reduction in cardiovascular death was 
achieved with 1 g n-3 PUFA daily compared to the control group after 3,5 years of 
intervention (141). Also in the recent JELIS primary prevention trial, 1.8 g of 
eicosapenthaenoic acid (EPA) daily in addition to statins reduced the risk of major coronary 
events by 19% compared to statins alone (142).  
 
From large observational studies, adherence to a Mediterranean dietary pattern has been 
associated with reduced all-cause mortality and mortality from coronary heart disease (143, 
144). In The Lyon Diet Heart Study, comprising 605 patients with a first myocardial 
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infarction, Mediterranean-style diet was associated with a 68% reduction in coronary events 
and deaths compared to Western-style diet (138).  
 
4.4.3. Anti-inflammatory effect of non-pharmacological interventions 
The mechanisms behind the protective effects of exercise, diet and n-3 PUFA 
supplementation are not fully explained. As inflammation seems to play a central role in the 
pathogenesis of metabolic syndrome, type 2 diabetes and atherosclerosis (85), it could be 
hypothesised that non-pharmacological interventions could have an anti-inflammatory effect.  
 
It has been speculated that some of the beneficial effects of n-3 PUFAs might be due to a 
more favourable fatty acid profile in membrane phospholipids of inflammatory cells (145). 
However, results on inflammatory markers from previous intervention studies have been 
conflicting, depending both on the dose of n-3 PUFA supplementation and the variables 
studied (146). Also the effect on inflammation by various dietary strategies has been 
conflicting, and the interpretation of especially calorie-restricted diet interventions is 
complicated as weight loss itself might reduce inflammation (147). Although Mediterranean-
like diet has been proposed to have a potentially anti-inflammatory effect (148), results from 
interventional studies have been conflicting (149, 150).   
 
Epidemiological studies have shown that increasing levels of physical activity are associated 
with reduced inflammation in healthy subjects (151, 152). Furthermore, in uncontrolled trials 
of various study populations, it has been shown that exercise can reduce circulating markers 
of inflammation (153, 154). Still, only a few published controlled trials have evaluated the 
effect of exercise on markers of inflammation in populations with and without the metabolic 
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syndrome (155). As both endurance training (156, 157) and strength training (158) have been 
shown to reduce the amounts of visceral fat, it could be hypothesised that such exercise 
would have a beneficial effect on inflammation in obese people. 
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5. Aims of the thesis 
5.1. Overall aim  
To investigate the role of inflammation and atherosclerosis in the metabolic syndrome, and 
potential effects of non-pharmacological interventions on inflammatory markers.  
 
5.2. Specific aims 
5.2.1 To investigate the role of inflammatory markers as potential predictors of 
cardiovascular events in subjects with the metabolic syndrome (Paper II). 
5.2.2 To investigate the effect of exercise on inflammatory markers in subjects with the 
metabolic syndrome, and a potential association with changes in adipose tissue compartments 
and components of the metabolic syndrome (Papers I and III). 
5.2.3 To investigate the effect of Mediterranean-like diet and very long-chain n-3 PUFA 
supplementation on inflammatory markers in a population of elderly high-risk men, and a 
potential association with changes in anthropometric measures and fatty acid profile (Paper 
IV). 
5.2.4 To investigate the impact of inflammation on metabolic syndrome-related arterial 
stiffness in elderly men (Paper V).  
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6. Material and methods 
6.1. Study subjects and design 
The Metabolic Syndrome and Anti-inflammatory effect of Training and Statin (SATS)-trial 
(paper I and III) took place at Nordland Hospital, Bodø in 2003. We studied 34 physically 
inactive men aged 20-75 years with the metabolic syndrome. Individuals with known 
coronary heart disease were excluded. Those treated with statins were either excluded, or 
statins were washed out for a period of 4 weeks before inclusion. The study subjects were 
recruited after advertisement in the local newspaper. The study had an unmasked randomised 
2x2 factorial design. The participants were randomised into 1 of 4 groups: control (n=6), 
exercise (n=9), pravastatin (n=9) or the combination of both interventions (n=10). Data were 
obtained at randomisation and after 12 weeks. Two of the participants, one in the pravastatin 
group and one in the combination group were withdrawn from the study due to side effects. 
As the study was not performed on an intention-to-treat basis, data from these two 
participants were excluded from the statistical analysis. The study was carried out in 
compliance with the Helsinki Declaration and was approved by the Regional Ethics 
Committee. All subjects gave their written informed consent to participate.  
 
In papers II, IV and V, we studied 563 elderly men age 64-76 years, 28% with known CVD, 
34% smokers and 39% with the metabolic syndrome, and a large proportion taking a broad 
spectrum of medication. The basis for recruitment into the present study was a follow up of 
the participants from the Oslo Diet and Anti-smoking study carried out in 1972-1977, 
comprising 1232 men with high risk of CVD. The survivors of this population were in 1997 
invited to participate in the Diet and Omega-3 Intervention Trial on Atherosclerosis (DOIT). 
In total, 910 survivors were contacted for screening, 655 attended the screening visit, and 563 
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were included. The study had a randomised 2x2 factorial design, and was placebo controlled 
for the n-3 PUFA capsules. The 563 participants were randomised into 1 of 4 groups: control 
group (n=142), dietary counselling and placebo capsules (n=139), n-3 PUFA capsules and no 
dietary counselling (n=140) and the combination of n-3 PUFA capsules and dietary 
counselling (n=142). Data were obtained at randomisation and after 36 months. After 3 years, 
487 subjects completed the study and were included in the treatment effect analyses. Of the 
remaining, 38 had died, 29 dropped out because of disease states interfering with study 
follow-up, and 9 individuals were unwilling to complete the study. The study was carried out 
in compliance with the Helsinki Declaration and was approved by the Regional Ethics 
Committee. All subjects gave their written informed consent to participate.  
 
 
6.2. Definition of the metabolic syndrome 
In all papers, we have used the definition by ATP-III of the National Cholesterol Education 
Program (NCEP) (1, 3) (Table 1). It should be noted that in paper I, we used the definition 
from 2001, in which the cut-off for fasting blood glucose was > 6.1 mmol/L, whereas in 
paper III also the 2005 version (using cut-off for glucose > 5.6 mmol/L) was cited, thus the 
participants met the criteria for both definitions.  
 
6.3. Intervention principles 
In papers I and III, we studied the effect of exercise, pravastatin and the combination of both 
interventions. The exercise programme took place in a training studio three times a week, 
mostly in supervised groups. The duration of each workout was 45-60 minutes. 
Approximately 40% of the scheduled workout was endurance training and 60% was strength 
training of large muscle groups such as thighs, back and abdomen. The participants were 
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encouraged to record the trainings in logs. As an estimate of compliance, oxygen 
consumption was measured before and after the intervention period. Participants in the 
pravastatin groups received 40 mg pravastatin per day. The pravastatin intervention was not 
placebo-controlled. As an estimate of compliance, lipid profile was obtained before and after 
the intervention period.  
 
In papers II, IV and V, we studied the effect of dietary counseling, very long-chain n-3 PUFA 
capsules and the combination of both interventions. The dietary counseling was undertaken 
on an individual basis and consisted of advice to increase the use of vegetable oil and 
margarines (rapeseed oil, olive oil and sunflower oil), vegetables, fruit and fish, and to 
decrease the use of meat and fat from animal sources. Special oil and margarine (VITA 
margarine; Norwegian Food Company Mills DA, Oslo) were specifically supplied to these 
participants at all visits. Overweight subjects were encouraged to adopt a calorie-restricted 
diet. As an estimate of compliance, food frequency questionnaires were recorded at baseline 
and 36 months. The dosage of n-3 PUFA supplementation was 2.4 g (4 capsules) daily, and 
the capsules (Picasol, Lube, Denmark) contained about 35% eicosapentaenoic acid (EPA; 
C20:5n-3), 20% docosahexaenoic acid (DHA; C22:6n-3) and 3.5 mg tocopherols/g to prevent 
fatty acid peroxidation. The placebo capsules (corn oil) contained 56% linoleic acid (18:2n-
6), 32% oleic acid (18:1n-9), 10% palmitic acid (16:0) and 4 mg tocopherols/g.  
 
6.4. Laboratory methods 
All clinical data and laboratory analyses were obtained before randomization and after the 
intervention period. Blood samples were drawn after an overnight fast, and plasma and serum 
were frozen at –70°C to –80°C until analysis. Circulating levels of inflammatory markers and 
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adipokines in plasma and serum were measured by commercially available enzyme 
immunoassays, as described in details in the papers. In paper IV, fatty acid composition in 
serum phospholipids was analysed by gas-liquid chromatography in a random subset of 
participants (n=278).  
 
In papers I and III, oxygen consumption was measured at 80% of estimated maximal heart 
rate, using the equation 220-age (years). Five recordings were made at the target frequency, 
and the median was used for statistical analyses. Quantification of subcutaneous and visceral 
fat compartments was performed by computerized tomography (CT). To minimize the 
amount of radiation, the CT scans were performed at only one site, corresponding to the disk 
between the 2nd and 3rd lumbar vertebrae, a level that has been shown to be closely correlated 
with visceral fat volume in men (159).  
 
In paper V, arterial stiffness was evaluated by brachial PWP measured by a 
photopletysmographic finger pulse-sensor (Medasonics, Mountain View, CA, USA) from the 
left third finger pulp, in fasting subjects and in a temperature-controlled room, as previously 
described (160). The photopletysmography device evaluates the perfusion down to 
approximately 2 mm below the surface by combining an infrared source and a detector. PWP 
was defined by the time (milliseconds) from the initiation of the QRS-complex from ECG to 
digital pulse initiation from the finger pulp. The data were computerised and stored digitally, 
and the mean of three pulse wave registrations was obtained. Recordings were excluded if 
signals were poor or unreadable, or subjects had atrial fibrillation.  
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6.5. Statistics 
As several biochemical markers were skewly distributed, non-parametric statistics were 
mainly used in papers I-IV, and detailed descriptions are given in the papers. In brief, 
differences between groups and differences in changes between groups were evaluated by 
Mann-Whitney U test, and Wilcoxon test was used to evaluate within group changes from 
baseline. Correlation analyses were performed using the Spearman method. In paper II, 
logistic regression analysis was used for calculation of adjusted odds ratios, and the chi 
squared linear by linear association was used for trend analyses. In papers III and V, 
Jonckheere-Terpstra test was used for trend analyses. In paper V, the main outcome variable 
(PWP) was normally distributed, and differences at baseline were evaluated with a t-test. 
Associations were analysed in a multiple linear regression model, and skewed data were log-
transformed before entered into the model. A two-tailed significance level of 0.05 was used. 
The statistical analyses were performed with SPSS software, version 15.0 (SPSS Inc, 
Chicago, USA). 
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7. Summary of results  
7.1. Paper I 
We investigated the effect of a 12 weeks intervention with physical exercise on circulating 
markers of inflammation in 34 subjects with the metabolic syndrome. Pravastatin was used for 
comparison due to its documented anti-inflammatory effect.  In the exercise group, there was 
a significant reduction in circulating levels of the chemokines MCP-1 (-33% vs. baseline, 
p=0.04 compared to no exercise) and IL-8 (-13% vs. baseline, p=0.007 vs. no exercise). 
Changes in MCP-1 were significantly correlated to changes in visceral fat (r=0.41, p=0.02). 
Our findings suggest that the protective effect of exercise might in part be due to suppression 
of the inflammatory process, and some of this effect might be mediated by a reduction in 
visceral fat. 
 
7.2. Paper II 
We investigated the role of inflammatory markers as potential predictors of cardiovascular 
events in subjects with and without the metabolic syndrome from the DOIT trial. The study 
comprised 563 elderly men with (n=221) and without (n=342) the metabolic syndrome. 
During 3 years, 68 cardiovascular events were recorded. In the total population, CRP, IL-18 
and IL-6 were elevated in subjects with events (p<0.01). In subjects with the metabolic 
syndrome, IL-18 was the strongest predictor (adjusted odds ratio 2.9 [95% CI 1.1-7.8]), 
whereas in subjects without metabolic syndrome, only CRP appeared an independent 
predictor (3.3 [1.5-7.3]). There was a significant interaction between fasting glucose and both 
IL-18 (p=0.008) and IL-6 (p=0.024), but not CRP in the cardiovascular risk prediction. 
Elevated fasting glucose markedly increased the predictive power of inflammatory markers, 
and for IL-18, there was a stepwise increase in event rate by quartiles of fasting glucose. 
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Taken together, our findings suggest a mutually potentiating effect of hyperglycaemia and 
inflammation in the cardiovascular risk prediction.  
 
7.3. Paper III 
As IL-18 has been identified as a strong predictor of cardiovascular events in subjects with 
the metabolic syndrome, we investigated the effect of exercise on serum levels of IL-18 in the 
study from paper I. Levels of IL-18 were reduced by exercise only (p=0.036), pravastatin 
only (p=0.036) and the combination (p=0.017) vs. baseline, however without inter-group 
differences. Still, the reduction of IL-18 in the exercise groups was not negligible (17.5%), 
and the reduction of IL-18 was significantly associated with improvement of an increasing 
number of components of the metabolic syndrome (p for trend =0.034). This effect is likely to 
be caused by exercise, as this intervention improved several components of the syndrome 
compared to the control group (p=0.029). Our findings suggest that the protective effect of 
exercise might in part be due to reduced levels of IL-18 associated with improvement of the 
metabolic syndrome and its components.  
 
 
7.4. Paper IV 
Although Mediterranean-like diet and n-3 PUFA supplementation have been reported to 
reduce the risk of cardiovascular mortality and morbidity, the mechanisms are not fully 
clarified. We studied the effect of dietary counseling, very long-chain n-3 PUFA intervention 
and both on circulating levels of inflammatory markers in the DOIT trial. Levels of IL-18 
were significantly decreased by diet (-10.5% vs. baseline, p=0.012 compared with no diet), 
and by n-3 PUFA supplementation (-9.9% vs. baseline, p=0.008 compared with placebo). 
Other measured inflammatory markers were not affected. Changes in IL-18 were significantly 
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but weakly correlated to changes in triglycerides (r=0.20, p<0.001), EPA (r=-0.14, p=0.030), 
DHA (r=-0.14, p=0.034), body mass index (BMI) (r=0.16, p<0.001) and waist circumference 
(r=0.12, p=0.007). Our findings suggest that the cardio-protective effects of Mediterranean-
like diet and n-3 PUFA supplementation might in part be explained by reduced levels of IL-
18, but probably beyond changes in serum fatty acids and body composition.  
 
7.5. Paper V 
Both arterial stiffness and inflammation have been shown to be associated with the metabolic 
syndrome and to predict cardiovascular events. As IL-18 seems to be particularly predictive 
of cardiovascular events in subjects with the metabolic syndrome, we aimed to investigate the 
influence of IL-18 and metabolic syndrome components on arterial stiffness in the DOIT 
population. At baseline, PWP was lower in subjects with the metabolic syndrome (p<0.001), 
reflecting increased arterial stiffness. Furthermore, an increasing number of metabolic 
syndrome components was significantly associated with lower PWP (p for trend < 0.001) and 
elevated levels of IL-18 (p for trend = 0.002). In a multivariate linear regression model, PWP 
was independently associated with IL-18 (p=0.021) and systolic blood pressure (p<0.001). 
Both arterial stiffness and IL-18 levels were improved by n-3 PUFA supplementation, as 
previously reported. Also changes in PWP after 36 months of intervention were 
independently associated with changes in IL-18 (p=0.021) and systolic blood pressure 
(p<0.001). The clinical importance of this clustering of metabolic syndrome components, 
inflammation and arterial stiffness, and the potential effect of n-3 PUFA supplementation 
warrant further investigation. 
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8. Discussion 
8.1 Methodological considerations 
8.1.1. General comments 
It should be noted that we have only studied Caucasian male subjects. The DOIT study was 
an extension of the Oslo Diet and Anti-smoking study, so the population was already defined. 
This population is quite heterogenic, with a large range of morbidity and use of medication 
that might influence the inflammatory process. Furthermore, the subjects consist of long time 
survivors from a high-risk population, raising the possibility of survivor bias that should be 
taken into account when interpreting the prediction of events in paper II.  
 
When planning the SATS study, we wanted the population to be as homogenous as possible 
to avoid too much biological variation to influence the intervention effect. However, we 
assumed quite wrongly that the metabolic phenotype with abdominal obesity and its related 
risk factors was a typical male problem. Indeed, it is now evident that the prevalence of 
metabolic syndrome is comparable in men and women, and that the syndrome probably 
contributes more to the relative cardiovascular risk in women (7, 32). Therefore, in retrospect, 
the SATS study should preferably have included also women. 
 
Although the same definition of the metabolic syndrome has been used, the populations are 
quite different, and not necessarily generalisable to other cohorts with the metabolic 
syndrome. The SATS study comprised middle-aged men, with a high proportion of diabetics, 
whereas the DOIT study comprised elderly long-time survivors of men with long-standing 
hypercholesterolemia. Still, the age-adjusted prevalence of the metabolic syndrome in the 
DOIT study is comparable to that published in a large Norwegian cohort (17).  
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8.1.2. SATS study (Papers I and III) 
The main limitation of the SATS study (paper I and III) is the small sample size, making the 
study especially vulnerable to type II statistical errors, and the study should be considered a 
pilot trial. While planning the study, we intended to perform a power analysis, which would 
have been appropriate. However, at this time point we could not identify any controlled study 
on the effect of exercise on inflammation (155). Thus, we were not certain about the effect 
estimate or which of the inflammatory markers that could be expected to change during the 
intervention period. As a practical solution, based on an uncontrolled study on the effect of 
exercise on circulating levels of adhesion molecules and MCP-1 in 12 subjects with heart 
failure (153), we aimed for including at least 30 participants, using the factorial design to 
increase the power in between-group analyses.  
 
Another limitation of paper I and III is that all clinical examinations, including 
anthropometric measurements were performed by the principal investigator. Waist 
circumference in particular, is vulnerable to bias, and the results should be interpreted with 
caution. However, the analyses of inflammatory markers and measurement of adipose tissue 
compartments on CT were blinded, and the main result should therefore be reliable. In the 
correlation analysis in paper I (Figure 2), one outlier can be seen that was included in the 
analysis. Removing this outlier did not change the result. In paper III, another outlier can be 
seen (Figures 1 and 2), which was excluded from the analysis. Including this outlier did not 
change any of the results substantially, except that the reduction from baseline in the 
combination group was no longer statistically significant, whereas the significance persisted 
when analysing according to the factorial design.  
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 8.1.3. DOIT study (Papers II and V)  
Limitations regarding the study population are discussed above. In paper II, it should be noted 
that our results represent a post hoc analysis from an intervention trial, although we have 
tested for interactions and adjusted for intervention principles as appropriate. Furthermore, it 
should be noted that this study was not powered for clinical endpoints. However, registration 
of clinical endpoints was according to protocol. Finally, the limited number of endpoints may 
increase the risk of type II errors, especially in sub-group analyses. Thus, the main result with 
the strong association between IL-18 and end points should be reliable. It should also be 
noted that we have included a large number of covariates in the logistic regression analyses 
compared to the low number of endpoints, partly because the referees wanted us to include 
the classical risk factors, and partly as we had to adjust for the intervention principle. 
Recalculating odds ratios using only the strongest covariates did not change the main result. 
 
The aims and objectives of paper V were considered important for penetrating potential 
mechanisms that could explain the obviously important role of IL-18 in the metabolic 
syndrome. Also in paper V, it should be noted that we have included a large number of 
covariates in the linear regression analysis compared to the size of the study cohort, but 
recalculating beta coefficients using only the strongest covariates did not change the main 
result. 
 
8.2. General discussion 
To simplify the discussion, paper II will be discussed first, followed by a common discussion 
of papers I and III, and finally papers IV and V. 
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8.2.1. Inflammatory markers and cardiovascular risk prediction in the metabolic 
syndrome 
In paper II, we showed that IL-18 was a strong predictor of cardiovascular events in elderly 
men with the metabolic syndrome. As pointed out in the discussion, it is not appropriate to 
generalise this result to the general population, as our study comprises only elderly Caucasian 
men, and as survivor bias might be present. However, Espinola-Klein et al reported similar 
findings from a large cohort consisting of men and women (n=1263, mean age 62 years) with 
documented coronary artery disease, with IL-18 being the only independent predictor for 
cardiovascular mortality in subjects with the metabolic syndrome (161). To our knowledge, 
no other studies have to date investigated the combined impact of IL-18 and metabolic 
syndrome on cardiovascular events.  
 
As pointed out in paper II, increased levels of CRP have been reported to add to the 
cardiovascular risk prediction of metabolic syndrome both in cross-sectional (87) and 
prospective studies (88, 89), whereas one prospective study could not find that the 
combination of elevated CRP and metabolic syndrome increased the predictive power (90). 
Langenberg et al investigated the combined impact of metabolic syndrome, adipokines and 
inflammatory markers on cardiovascular death in men and women during 20 years of follow-
up (n=2118, age 40-95 years), and showed that IL-6 but not CRP remained a significant 
predictor when including both markers in multivariate analyses (162). In accordance with 
Espinola-Klein and Langenberg also we included all the inflammatory markers (IL-6, IL-18 
and CRP) in the same model, but when excluding IL-18 from the model, also IL-6 (adjusted 
OR 2.7 [95% CI 1.1, 7.0]) and CRP (2.9 [1.1, 8.0]) became independent predictors in subjects 
with the metabolic syndrome. Thus, although CRP has been identified as the most consistent 
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inflammatory marker in predicting cardiovascular events (64, 73, 163, 164), this marker 
seems to disappear as an independent predictor in metabolic syndrome when including IL-18 
and possibly IL-6 in the same model (161, 162). Hence, it seems like CRP is a more global 
marker of CVD, whereas IL-18, and possibly IL-6 seem to be more predictive in the presence 
of the metabolic syndrome. All studies taken together, inflammatory markers probably add to 
the CVD risk of the metabolic syndrome, but which of the markers that add most to the risk 
remains to be determined.  
 
Another question is whether inflammation causes atherosclerosis or the other way around, or 
if other factors associated with the metabolic syndrome might cause both inflammation and 
CVD. As shown in Figure 4, systemic inflammation might be caused by both cytokines from 
the atherosclerotic plaque and other sources such as adipose tissue (41). The fact that CRP is 
downstream of the cytokine cascade from the atherosclerotic plaque could in part explain the 
robustness of this marker in predicting CVD. Furthermore, inflammatory markers are 
associated with other risk factors such as smoking, obesity, diabetes and hypertension (165). 
Thus, although inflammatory markers are highly predictive of cardiovascular events, it 
remains unknown whether inflammation is a causative factor, a marker of the rupture-prone 
plaque or if the association is explained by unknown confounding factors.  
 
In our study, we found a significant interaction between fasting glucose and both IL-18 and 
IL-6, but not CRP in the cardiovascular risk prediction. Thus, a potentiating proatherogenic 
effect of hyperglycemia and inflammation could be a possibility, and perhaps different 
inflammatory markers are affected differently.  
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Experimental hyperglycemia has been shown to increase concentrations of various cytokines, 
including IL-18, in humans (166). Our results expand these findings by suggesting that 
hyperglycemia not only increases levels of IL-18, but also fuels the potential harmful effects 
of a given cytokine level. IL-18 can stimulate both type 1 helper T (Th1) and Th2 responses 
depending on its cytokine milieu and acts synergistically with IL-12 to stimulate a Th1 
response with production of interferon gamma, a central feature in the atherosclerotic lesion 
(68). Recently, levels of IL-12 have been reported to be increased in subjects with type 2 
diabetes and by experimental hyperglycemia (167, 168). As several pro-inflammatory 
markers were elevated in subjects with the metabolic syndrome, we speculate that our 
findings could in part be explained by a Th1 response mediated by IL-18 acting in synergy 
with a hyperglycemic pro-inflammatory milieu. Also other cells are likely to be involved, and 
it has been shown that the proatherogenic effects of CRP were potentiated by hyperglycemia, 
by increased expression of adhesion molecules and MCP-1 in endothelial cells (169).  
 
8.2.2. Effects of exercise on markers of inflammation 
In paper I, we showed that a combination of strength and endurance training had an anti-
inflammatory effect by reducing plasma levels of the chemokines MCP-1 and IL-8. At the 
time of submission, we could not identify any other controlled study that showed a similar 
effect, and our small pilot study is still one of few controlled trials on the effect of exercise on 
inflammation (155). However, in uncontrolled studies on different populations, exercise has 
been shown to decrease levels of MCP-1, IL-8, CRP and TNF-, and to increase adiponectin 
levels (153, 154, 170, 171). The last years, also some controlled trials have been performed, 
with conflicting results on circulating inflammatory markers in various populations (155, 
172-175).  
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In paper III, we showed reduced serum levels of IL-18 by pravastatin, exercise and the 
combination vs. baseline, however not in between group comparisons. A recent publication 
reported reduced levels of CRP and IL-18 by exercise in obese subjects with type 2 diabetes 
(174). Our study expands these findings by showing a significant association between 
reduction of IL-18 levels and improved number of metabolic syndrome components, and by a 
potentially additive effect of pravastatin and exercise on the IL-18 reduction. 
 
8.2.3. Effects of Mediterranean-like diet and very long-chain omega-3 fatty acids on 
markers of inflammation 
In paper IV, we showed that both Mediterranean-like diet and very long chain n-3 PUFA 
supplementation for 36 months reduced serum levels of IL-18, whereas the other 
inflammatory markers and adipokines studied were not affected. It could be discussed if it is 
appropriate to highlight this finding, as multiple statistical tests were performed. However, in 
light of the results from other papers in this thesis and the existing literature, IL-18 seems to 
be a particularly important player, and the observed reduction fits with the overall picture. 
Furthermore, it seems more difficult to obtain an intervention effect in populations with 
frequent use of medication. Hence, no effect of Mediterranean-like diet on levels of CRP or 
fibrinogen in subjects under treatment for coronary heart disease has been reported (150), 
whereas another study showed beneficial effect of Mediterranean-like diet on levels of CRP, 
IL-6 and IL-18 in a medication-free population with the metabolic syndrome (149).  
 
Previous reports on the effect of n-3 PUFA supplementation on markers of inflammation have 
been conflicting (146). Studies from our group have shown that although moderate doses (2.4 
g/day) of n-3 PUFAs might have beneficial effect on circulating levels of adhesion molecules 
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(176), the contrary might be seen with higher doses (4.9-5.1 g/day) (177, 178). It should also 
be noted that n-3 PUFA supplementation in high doses (4 g daily) has been reported to 
transiently increase fasting glucose in patients with diabetes (179), whereas long term 
metabolic effects with comparable doses (3.4 d/day) have been shown to be safe in patients 
with coronary artery disease (180). Moreover, low to moderate doses (2 g daily) have been 
reported to improve insulin sensitivity in healthy individuals (181).  
 
A reduction in serum levels of IL-18 by very long-chain n-3 PUFA supplementation has not 
been reported before, to the best of our knowledge. The fact that other inflammatory markers 
were not affected by this intervention with moderate doses of n-3 PUFAs (2.4 g daily) could 
in part be due to the frequent use of medication as mentioned above, but it could also be that 
n-3 PUFAs act differently on the various inflammatory markers. In contrast to most other 
cytokines, IL-18 is expressed constitutively in many cell types as a precursor, pro-IL18, 
which is inactive until cleaved by the enzyme caspase-1 (68). n-3 PUFAs might inhibit 
inflammatory gene expression via inhibition of nuclear factor B, and recent reports suggest 
that this transcription factor is probably involved in the activation of caspase-1 (137, 182). 
Furthermore PUFAs, especially EPA and DHA, are natural ligands for peroxysome 
proliferator activated receptors (PPAR), which in activated state inhibit nuclear factor B and 
thus several inflammatory processes (137, 183). Thus, both PPAR activation and inhibition of 
the nuclear factor B pathway could contribute at least indirectly to the reduction of IL-18 
levels by n-3 PUFAs.  
 
Although not discussed in paper IV, in subgroup analysis of subjects with the metabolic 
syndrome, we observed a similar reduction of IL-18 levels by both interventions, however not 
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statistically significant. When classifying all study participants according to improvement of 
0, 1, 2, 3, 4 or 5 components of the syndrome (defined as more than median decrease in 
triglycerides, systolic blood pressure, glucose and waist circumference, or increase in HDL, 
respectively), reduced levels of IL-18 were significantly associated with improvement of an 
increasing number of components, as discussed in paper V (Figure 5). In subgroup analysis, 
this association was still significant in subjects who underwent dietary intervention (p for 
trend <0.001), but not in subjects receiving n-3 PUFA supplementation.  
 
 
 
Figure 5. Changes in serum levels of IL-18 by number of metabolic syndrome components 
that improved during the intervention period in the total population (p for trend < 0.001). 
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8.2.4. Additive effect of lifestyle interventions? 
In papers III and IV, we showed a potentially additive effect of the intervention principles on 
levels of IL-18 (exercise and pravastatin, diet and n-3 PUFA supplementation, respectively). 
The combination of diet and exercise was not studied in this thesis. However, in paper III and 
IV, we showed a significant association between reduced levels of IL-18 and improvement of 
an increasing number of components of the metabolic syndrome by both exercise and diet 
intervention. Regardless of intervention principle, the question remains whether an improved 
metabolic control leads to reduced inflammation or the other way around, or if improvement 
of body composition has a beneficial effect both on inflammation and components of the 
metabolic syndrome. Moreover, it could be speculated that a non-intended change in diet 
occurred in the exercise groups in papers I and III. However, as dietary counselling was not 
part of the intervention, data about eating patterns were not recorded. Conversely, data about 
physical activity were not monitored in paper IV, although differences in physical activity 
between the groups are less likely, as the dietary intervention was on an individual basis. 
 
Several intervention studies have examined the combined effect of diet and exercise 
intervention in obese individuals. Taken together, most studies show that a combined 
intervention reduces levels of several pro-inflammatory markers and increases adiponectin 
levels (155, 184-187), although some studies report effect of diet only with no additional 
effect of exercise (188, 189). On the other hand, a recent study showed that the combination 
of diet and exercise but not diet alone reduced several inflammatory markers, although the 
reduction in visceral fat was equal in all intervention groups (190). Thus, exercise could exert 
its effect through alternative mechanisms such as decreased expression of cytokines in muscle 
tissue or reduced chronic oxidative stress (191, 192).  
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Interestingly, a combined intervention with Mediterranean-like diet and increased physical 
activity maintained a weight reduction and decreased levels of CRP and IL-18 in obese 
women during two years follow up (193). Lifestyle interventions consisting of diet and 
exercise have been shown to improve several cardiovascular risk factors including the 
metabolic syndrome and to reduce the risk of developing type 2 diabetes (126, 194). Hence, 
current guidelines highlight the combination of increased physical activity (at least 30 
minutes on most days of the week) and improved diet (decreased intake of saturated fat and 
simple carbohydrates, increased intake of fruits, vegetables, whole grain and fish) to achieve 
a sustained weight loss and reversal of the components of the syndrome (3). Our findings 
suggest that some of the protective effect of these lifestyle modifications might be due to 
decreased inflammation associated with improved body composition and components of the 
metabolic syndrome. 
 
8.2.6. Arterial stiffness, inflammation and the metabolic syndrome 
In paper V, we showed that arterial stiffness evaluated by PWP was more pronounced in 
subjects with the metabolic syndrome, associated with an increasing number of metabolic 
syndrome components and independently associated with IL-18. Although the metabolic 
syndrome has been shown to be associated with both arterial stiffness and a pro-inflammatory 
state, such a clustering of IL-18, arterial stiffness and metabolic syndrome has to our 
knowledge not been reported previously.  
 
One crucial question is whether or not such a clustering has importance for cardiovascular 
risk prediction. A clustering of arterial stiffness, metabolic syndrome and inflammation 
measured by erythrocyte sedimentation rate was recently reported from a cohort of ischaemic 
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stroke patients (195). In paper II, we showed that IL-18 was particularly predictive of 
cardiovascular events in subjects with hyperglycemia. However, there was no significant 
association between fasting glucose and PWP, and increased arterial stiffness did not appear 
to increase the predictive power of IL-18 in the present study (data not shown). Although 
arterial stiffness has been shown to predict cardiovascular events in several studies, the most 
consistent evidence come from studies on aortic stiffness, measured by carotid-femoral pulse 
wave velocity (106-112, 195), whereas brachial PWP was measured in the DOIT study.  
 
As already mentioned, it should be noted that we have studied an elderly population.  
Arterial stiffness is in part implicated in the normal ageing process (196), and as the 
metabolic syndrome is also more prevalent in elderly, the observed clustering could in part be 
explained by the age group of the study population.  
 
The title of paper V indicates an independent association not only between arterial stiffness 
and IL-18, but also with components of the metabolic syndrome. Although not elaborated in 
the paper due to space constraints, there was an independent association between PWP and 
increasing number of metabolic syndrome components, also after adjustment for age, 
smoking, CVD, statins, ACE-inhibitors and IL-18. Among these components, only systolic 
blood pressure was independently associated with PWP, as previously reported (176).  
 
The precise mechanisms of increased arterial stiffness in diabetes and metabolic syndrome 
are largely unknown. One of the main mechanisms thought to be involved is the formation of 
advanced glycation end products in the arterial wall, causing cross-linking of collagen, which 
may cause loss of arterial wall elasticity (197). Another proposed mechanism is that chronic 
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hyperglycemia and hyperinsulinemia might increase the activity of the renin-angiotensin-
aldosterone axis, which might contribute to hypertrophy and fibrosis (198). Endothelial 
dysfunction might also contribute to arterial stiffening, in part due to decreased local 
availability of the endogenous vasodilator nitric oxide, and increased activity of 
vasoconstrictors such as endothelin-1 (199-201).  
 
As low-grade inflammation impairs endothelial function (124), it has been proposed that 
inflammation might be an important contributor to arterial stiffness in the metabolic 
syndrome (115). Our findings suggest that this might be the case, and that IL-18 might be an 
important player: Adding other inflammatory markers and adipokines such as CRP, IL-6, 
PAI-1 and adiponectin to the regression model did not change the beta-coefficient of IL-18, 
whereas none of the other markers were independently associated with PWP (data not 
shown).  
 
Interestingly, both arterial stiffness (160) and levels of IL-18 (paper IV) were improved by n-
3 PUFA supplementation in this trial, whereas IL-18 but not arterial stiffness was improved 
by diet intervention. Changes in PWP after 36 months of intervention were independently 
associated with changes in IL-18, and there was a significant association between an 
increasing number of metabolic syndrome components that improved and decreasing IL-18 
levels (Figure 5) and reduced arterial stiffness. However, the association between reduced IL-
18 levels and improvement of metabolic syndrome components was only significant in 
subjects who underwent dietary intervention (p for trend <0.001), and not in subjects 
receiving n-3 PUFA supplementation, as discussed above. Also the association between 
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increased PWP and improvement of metabolic syndrome components was present in the diet 
group (p for trend =0.05), but not in the n-3 PUFA group.  
 
Separate studies should be undertaken in different populations to assess the clinical 
importance of the clustering of arterial stiffness, inflammation and the metabolic syndrome, 
and the potential effects of treatment. Although diet intervention might explain the 
association with improvement of metabolic syndrome components, n-3 PUFA 
supplementation might be the most suitable intervention for effective treatment of both 
arterial stiffness and IL-18 levels. 
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9. Conclusions  
1. Inflammatory markers and IL-18 in particular, strongly predict cardiovascular events 
in elderly men with the metabolic syndrome, and even more pronounced in the 
presence of elevated fasting glucose. Our results suggest a potentiating effect of 
inflammation and hyperglycemia in the cardiovascular risk prediction. This could 
have clinical importance for the risk stratification of subjects not only with the 
metabolic syndrome, but also with impaired fasting glucose and diabetes mellitus 
(paper II). 
2. Exercise reduced levels of MCP-1, IL-8 (paper I) and IL-18 (paper III). The reduction 
of MCP-1 was associated with a reduction in visceral fat, whereas the IL-18 reduction 
was associated with an improvement in components of the metabolic syndrome. As 
inflammatory markers and IL-18 in particular, strongly predict cardiovascular events 
in patients with the metabolic syndrome, our results point to exercise as an important 
intervention principle in reducing cardiovascular risk in this population. 
3. Mediterranean-like diet and very long-chain n-3 PUFA supplementation reduced 
serum levels of IL-18 in elderly high-risk men, whereas other inflammatory markers 
were not influenced (paper IV). Changes in IL-18 were significantly but weakly 
correlated with changes in body composition and serum fatty acids, and also 
associated with an improvement in components of the metabolic syndrome. Our 
results might explain some of the mechanisms behind the cardio-protective effect of 
these intervention principles, and point to Mediterranean-like diet and n-3 PUFA 
supplementation as important life-style interventions in high-risk individuals with and 
without the metabolic syndrome. 
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4. There was a tendency to additive effect of the intervention principles (pravastatin and 
exercise, diet and n-3 PUFA supplementation, respectively) regarding the reduction of 
IL-18 levels (papers III and IV), implying that a combination of these interventions 
could have a beneficial effect. 
5. Arterial stiffness was more pronounced in subjects with the metabolic syndrome, 
associated with an increasing number of metabolic syndrome components and 
independently associated with IL-18 both cross sectionally and longitudinally after 36 
months of intervention (paper V). Our data suggest that IL-18 contributes to arterial 
stiffness in the metabolic syndrome. Hence, IL-18 and arterial stiffness might be 
potential therapeutic targets in this population. 
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10. Future perspectives 
1. It remains to determine whether inflammatory markers and IL-18 in particular, are 
causative players or just markers of events in a population with the metabolic 
syndrome. A randomised controlled trial powered for clinical endpoints could 
answer this question. A combination of diet and exercise might be the most 
suitable intervention for reduction of IL-18 levels. 
2. The potentiating effect of inflammation and elevated glucose in cardiovascular 
risk prediction remains to be elucidated. In vitro experiments with inflammatory 
cells being stimulated with IL-18 and IL-6 in the presence and absence of 
hyperglycemia, and with a range of readouts are currently ongoing, and could give 
valuable information about the mechanisms involved.  
3. It remains to determine to what extent systemic inflammation and metabolic 
syndrome components are influenced by the quantity or activity of adipose tissue. 
Two studies are currently undergoing: One substudy from the DOIT cohort, 
comparing mRNA expression of inflammatory markers in adipose tissue from 
individuals with and without the metabolic syndrome, and a study of bariatric 
surgery patients in collaboration with Nordland Hospital, comparing the impact of 
quantity (on CT scan) and activity (mRNA expression) of visceral and 
subcutaneous adipose tissue compartments on systemic inflammation. 
4. The clinical importance of the clustering of IL-18, arterial stiffness and metabolic 
syndrome remains to be elucidated. A randomised controlled trial powered for 
clinical endpoints could answer this question. An intervention with n-3 PUFA 
capsules might be the most suitable intervention for improvement of both arterial 
stiffness and IL-18 levels. 
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